Mark A. Grabarczyk, MD

PCI with and without Abciximab after Upstream Eptifibatide Use: Outcomes in High-Risk Patients

08/01/2008

Matthew T. Sacrinty , MPH;

Robert J. Applegate , MD;

Talal T. Baki , MD;

William C. Little , MD;

Sanjay K. Gandhi , MD, PhD;

Michael A. Kutcher , MD, FACC, FSCAI;

David C. Sane , MD;

Mark A. Grabarczyk , MD;

Jason E. Goodin , BA;

Sidney Statonk , MD;

Several clinical trials have demonstrated that platelet glycoprotein (GP) IIb/IIIa receptor inhibition reduces the ischemic complications of percutaneous coronary interventions (PCI).1–4 Comparative data between agents, however, are very...

Several clinical trials have...

08/01/2008

Journal of Invasive Cardiology

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

March 27 ⁠–⁠ March 30

See Full Calendar

Mark A. Grabarczyk, MD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products